404 related articles for article (PubMed ID: 27250825)
41. Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-β/Smad3 signaling.
Sassoli C; Chellini F; Pini A; Tani A; Nistri S; Nosi D; Zecchi-Orlandini S; Bani D; Formigli L
PLoS One; 2013; 8(5):e63896. PubMed ID: 23704950
[TBL] [Abstract][Full Text] [Related]
42. The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate.
Wang C; Kemp-Harper BK; Kocan M; Ang SY; Hewitson TD; Samuel CS
Front Pharmacol; 2016; 7():91. PubMed ID: 27065874
[TBL] [Abstract][Full Text] [Related]
43. Assessment of renal fibrosis and anti-fibrotic agents using a novel diagnostic and stain-free second-harmonic generation platform.
Bhuiyan S; Shen M; Chelvaretnam S; Tan AY; Ho G; Hossain MA; Widdop RE; Samuel CS
FASEB J; 2021 May; 35(5):e21595. PubMed ID: 33908676
[TBL] [Abstract][Full Text] [Related]
44. Inhibitory effects of relaxin on cardiac fibroblast-to-myofibroblast transition: an electrophysiological study.
Squecco R; Sassoli C; Garella R; Chellini F; Idrizaj E; Nistri S; Formigli L; Bani D; Francini F
Exp Physiol; 2015 Jun; 100(6):652-66. PubMed ID: 25786395
[TBL] [Abstract][Full Text] [Related]
45. Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes.
Ng HH; Leo CH; Parry LJ; Ritchie RH
Front Pharmacol; 2018; 9():501. PubMed ID: 29867503
[TBL] [Abstract][Full Text] [Related]
46. Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor.
Ang SY; Hutchinson DS; Patil N; Evans BA; Bathgate RAD; Halls ML; Hossain MA; Summers RJ; Kocan M
Br J Pharmacol; 2017 May; 174(10):1077-1089. PubMed ID: 27243554
[TBL] [Abstract][Full Text] [Related]
47. Characterizing relaxin receptor expression and exploring relaxin's effect on tissue remodeling/fibrosis in the human bladder.
Diaz EC; Briggs M; Wen Y; Zhuang G; Wallace SL; Dobberfuhl AD; Kao CS; Chen BC
BMC Urol; 2020 Apr; 20(1):44. PubMed ID: 32321501
[TBL] [Abstract][Full Text] [Related]
48. Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist.
Dschietzig T; Bartsch C; Stangl V; Baumann G; Stangl K
FASEB J; 2004 Oct; 18(13):1536-8. PubMed ID: 15289446
[TBL] [Abstract][Full Text] [Related]
49. Relaxin Inhibits the Cardiac Myofibroblast NLRP3 Inflammasome as Part of Its Anti-Fibrotic Actions via the Angiotensin Type 2 and ATP (P2X7) Receptors.
Tapia Cáceres F; Gaspari TA; Hossain MA; Samuel CS
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806076
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of relaxin's antifibrotic action by SELDI-TOF mass spectrometry-based profiling of relaxin knockout mice, a model of progressive fibrosis.
Giannakis E; Macris M; Chan L; Tregear GW; Samuel CS; Wade JD
Ann N Y Acad Sci; 2009 Apr; 1160():350-2. PubMed ID: 19416218
[TBL] [Abstract][Full Text] [Related]
51. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity.
Pini A; Shemesh R; Samuel CS; Bathgate RA; Zauberman A; Hermesh C; Wool A; Bani D; Rotman G
J Pharmacol Exp Ther; 2010 Dec; 335(3):589-99. PubMed ID: 20826567
[TBL] [Abstract][Full Text] [Related]
52. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo.
Williams EJ; Benyon RC; Trim N; Hadwin R; Grove BH; Arthur MJ; Unemori EN; Iredale JP
Gut; 2001 Oct; 49(4):577-83. PubMed ID: 11559657
[TBL] [Abstract][Full Text] [Related]
53. Relaxin and the extracellular matrix: molecular mechanisms of action and implications for cardiovascular disease.
McGuane JT; Parry LJ
Expert Rev Mol Med; 2005 Sep; 7(21):1-18. PubMed ID: 16191259
[TBL] [Abstract][Full Text] [Related]
54. Opposite actions of urotensin II and relaxin-2 on cellular expression of fibronectin in renal fibrosis: A preliminary experimental study.
Cernaro V; Medici MA; Bianco F; Santoro D; Lacquaniti A; Romeo A; Lucisano S; Buemi A; Buemi M
Clin Exp Pharmacol Physiol; 2017 Oct; 44(10):1069-1071. PubMed ID: 28613403
[TBL] [Abstract][Full Text] [Related]
55. Relaxin induces matrix metalloproteinase-9 through activation of nuclear factor kappa B in human THP-1 cells.
Ho TY; Bagnell CA
Ann N Y Acad Sci; 2005 May; 1041():314-6. PubMed ID: 15956726
[TBL] [Abstract][Full Text] [Related]
56. A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity.
Praveen P; Wang C; Handley TNG; Wu H; Samuel CS; Bathgate RAD; Hossain MA
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047588
[TBL] [Abstract][Full Text] [Related]
57. Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism.
Yuan S; Guo D; Liang X; Zhang L; Zhang Q; Xie D
Front Cell Dev Biol; 2023; 11():1131481. PubMed ID: 37123405
[TBL] [Abstract][Full Text] [Related]
58. Relaxin regulates collagen overproduction associated with experimental progressive renal fibrosis.
Samuel CS; Mookerjee I; Masterson R; Tregear GW; Hewitson TD
Ann N Y Acad Sci; 2005 May; 1041():182-4. PubMed ID: 15956704
[TBL] [Abstract][Full Text] [Related]
59. Relaxin's physiological roles and other diverse actions.
Sherwood OD
Endocr Rev; 2004 Apr; 25(2):205-34. PubMed ID: 15082520
[TBL] [Abstract][Full Text] [Related]
60. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo.
Unemori EN; Pickford LB; Salles AL; Piercy CE; Grove BH; Erikson ME; Amento EP
J Clin Invest; 1996 Dec; 98(12):2739-45. PubMed ID: 8981919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
